case_images: PMC10830683_01
case_images: Laboratory values, organ dysfunction and interventions. The patient demonostrated thromobocytopenia on admission (A). When organ dysfunctioned worsened on HD#3 (B) additional laboratory values demonstrated coagulopathy and hyperbilirubinemia. Immune suppressive therapies were initiated late on HD#3 and the first dose of emapalumab was administered on HD#4 (C).
case_images: fped-11-1340360-g001.jpg
case_images: PMC10830683_03_fped-11-1340360-g001.jpg
case_images: F1
case_images: Even prior to the administration of the second dose of emapalumab, the ferritin levels started to decline, indicating a decrease in macrophage activation (Figure 1C).
case_images: PMC10830683_02
case_images: PMC10830683_03
case_images: Laboratory values, organ dysfunction and interventions. The patient demonostrated thromobocytopenia on admission (A). When organ dysfunctioned worsened on HD#3 (B) additional laboratory values demonstrated coagulopathy and hyperbilirubinemia. Immune suppressive therapies were initiated late on HD#3 and the first dose of emapalumab was administered on HD#4 (C).
case_images: fped-11-1340360-g001.jpg
case_images: PMC10830683_03_fped-11-1340360-g001.jpg
case_images: F1
case_images: Even prior to the administration of the second dose of emapalumab, the ferritin levels started to decline, indicating a decrease in macrophage activation (Figure 1C).